Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Long-term protection of mice surviving the i.p. challenge with viable tumor cells.

From: Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity

Group Number of micea Proportion of survivors (%)b Average survival AM ± SE (days) p-valuec
Control 27 0.0 18.00 ± 1.14  
1 × 90d* 8 75.0 83.75 ± 10.96 <0.0001
2 × 90d* 14 85.7 92.86 ± 4.91 <0.0001
3 × 90d* 19 73.7 90.89 ± 4.25 <0.0001
1 × 60d** 6 66.7 73.00 ± 17.08 <0.0001
2 × 60d** 16 87.5 92.50 ± 5.35 <0.0001
3 × 60d** 16 81.3 90.19 ± 5,63 <0.0001
1 × 30d*** 7 57.1 79.14 ± 12.10 <0.0001
2 × 30d*** 15 80.0 94.20 ± 12.38 <0.0001
3 × 30d*** 20 100.0 100.00 ± 0.00 <0.0001
  1. Mice surviving the i.p. challenge with 5 × 105 B16F1 viable tumor cells were re-challenged with the same number of viable tumor cells without additional treatment.
  2. a number of animals which survived 100 days after first tumor challenge
  3. b surviving animals - are animals which survived at least 100 days after tumor challenge
  4. c p-value: group compared to control group
  5. * vaccination started 90 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days interval
  6. ** vaccination started 60 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days interval
  7. *** vaccination started 30 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) in 15 days interval or three times (3×) in 15 days interval, except for the last vaccination, which was performed 7 days after second vaccination
  8. The experiment was repeated three times.